In a recent study, the Hermeking group identified the squalene epoxidase (SQLE), a rate-limiting enzyme in the cholesterol biosynthesis, as a candidate target in colorectal cancer that harbors p53 mutation and elevated MYC activity 4. The gene discussed is SQLE; the disease is colorectal cancer.